Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 5/20 | 0.41 |
| ▸ | HRH1 | P35367 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10606848 | 0.97 | MGLL (0.48) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL3284899 | 0.97 | MGLL (0.48) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL11159668 | 0.96 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL3282334 | 0.96 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10605784 | 0.95 | MGLL (0.50) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL10605772 | 0.95 | MGLL (0.50) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL8453928 | 0.93 | MGLL (0.46) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL8453923 | 0.93 | MGLL (0.46) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL8448547 | 0.93 | MGLL (0.46) | MGLLPOLBKDM4EHTTKMT2A | |
| SCHEMBL5348508 | 0.93 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2026-02-26 | — | — | US | disclosed |
| CN-117510512-A | Polysubstituted tetrahydroisoquinoline compound, preparation method, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024022528-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2024-02-01 | — | — | WO | disclosed |
| EP-3933009-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-08-16 | — | — | EP | disclosed |
| EP-3933009-A1 | LIQUID CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3839008-A1 | LIQUID CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3502210-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-09-09 | — | — | EP | disclosed |
| EP-3502210-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-8883037-B2 | Chiral compounds, cholesteric and ferroelectric liquid crystal compositions comprising these chiral compounds, and liquid crystal displays comprising these liquid crystal compositions | TETRAGON LC CHEMIE AG (LI) | 2014-11-11 | — | — | US | disclosed |
| US-8883037-B2 | Chiral compounds, cholesteric and ferroelectric liquid crystal compositions comprising these chiral compounds, and liquid crystal displays comprising these liquid crystal compositions | TETRAGON LC CHEMIE AG (LI) | 2014-11-11 | — | — | US | disclosed |
| US-7713437-B2 | Liquid crystal composition, liquid crystal element, reflective display material, and light-controlling material | FUJIFILM CORPORATION (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713437-B2 | Liquid crystal composition, liquid crystal element, reflective display material, and light-controlling material | FUJIFILM CORPORATION (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070278449-A1 | Liquid crystal composition, liquid crystal element, reflective display material, and light-controlling material | FUJIFILM CORPORATION | 2007-12-06 | — | — | US | disclosed |
| US-20070278449-A1 | Liquid crystal composition, liquid crystal element, reflective display material, and light-controlling material | FUJIFILM CORPORATION | 2007-12-06 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TFEB, SNCA, PARK7 | MGLL 1187/4885POLB 2209/4885KDM4E 2547/4885 |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | MGLL 2307/4885POLB 831/4885KDM4E 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.